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Abstract. In 1951 Robbins and Monro published the seminal article
on stochastic approximation and made a specific reference to its ap-
plication to the “estimation of a quantal using response, nonresponse
data.” Since the 1990s, statistical methodology for dose-finding studies
has grown into an active area of research. The dose-finding problem
is at its core a percentile estimation problem and is in line with what
the Robbins–Monro method sets out to solve. In this light, it is quite
surprising that the dose-finding literature has developed rather inde-
pendently of the older stochastic approximation literature. The fact
that stochastic approximation has seldom been used in actual clinical
studies stands in stark contrast with its constant application in engi-
neering and finance. In this article, I explore similarities and differences
between the dose-finding and the stochastic approximation literatures.
This review also sheds light on the present and future relevance of
stochastic approximation to dose-finding clinical trials. Such connec-
tions will in turn steer dose-finding methodology on a rigorous course
and extend its ability to handle increasingly complex clinical situations.
Key words and phrases: Coherence, dichotomized data, discrete bar-
rier, ethics, indifference interval, maximum likelihood recursion, unbi-
asedness, virtual observations.
1. INTRODUCTION
Dose-finding in phase I clinical trials is typically
formulated as estimating a prespecified percentile
of a dose-toxicity curve. That is, the objective is to
identify a dose θ such that π(θ) = p, or equivalently,
θ = π−1(p),(1)
where π(x) is the probability of toxicity at dose x
and is assumed continuous and increasing in x. Per-
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centile estimation, often seen in bioassay, is a well-
studied problem for which statisticians have an ex-
tensive set of tools; see the books by Finney (1978)
and Morgan (1992). There are, however, two practi-
cal aspects of clinical studies that distinguish phase
I dose-finding from the classical bioassay problem.
First, the experimental units are humans. An impli-
cation is that the subjects should be treated sequen-
tially with respect to some ethical constraints (e.g.,
Section 2.3.1). As such, dose-finding is as much a de-
sign problem as an analysis problem. Second, the ac-
tual doses administered to the subjects are confined
to a discrete panel of levels, denoted by {d1, . . . , dK},
with π(d1) < · · · < π(dK). Therefore, it is possible
that π(dk) 6= p for all k, and the working objective
then is to identify the dose
ν = argmin
dk
|π(dk)− p|.(2)
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Apparently, the continuous dose-finding objective θ
and the discrete objective ν are close to each other.
However, in this article, we will see that discretized
versions of methods developed for θ are not neces-
sarily good solutions for ν. This special section of
Statistical Science also consists of four other articles
that review some benchmarks in the recent develop-
ment of the so-called model-based methods for dose-
finding studies. In a nutshell, a model-based method
makes dose decisions based on the explicit use of a
dose-toxicity model. That is, the toxicity probabil-
ity at dose x, π(x), is postulated to be F (x,φ0) for
some true parameter value φ0. This is in contrast
to the class of algorithm-based designs whereby a
set of dose-escalation rules are prespecified for any
given dose without regard to the observations at the
other doses. Section 2 of this article will present a
brief history of the development of the modern dose-
finding methods and define the scope of this special
issue.
In addition, this article complements the other
articles in two ways. First, it consolidates the key
theoretical dose-finding criteria that are otherwise
scattered in the literature (Section 2.3). Second, it
compares and contrasts the dose-finding literature
with the large literature on stochastic approxima-
tion (Section 3); the former primarily addresses the
discrete objective ν, whereas the latter deals with
θ. While this literature synthesis is of intellectual
interest, it also sheds light on how we may tailor
the well-studied stochastic approximation method
to meet the practical needs in dose-finding studies
(Section 4). Section 5 will end this article with some
future directions in dose-finding methodology.
2. MODERN DOSE-FINDING METHODS
2.1 A Brief History
This article uses the work of Storer and DeMets
(1987) as a historical line to define the modern statist-
ical literature of dose-finding. Little discussion and
formal formulation of the dose-finding problem ex-
isted in the pre-1987 statistical literature; an excep-
tion was the article by Anbar (1984). While dose-
finding in cancer trials was discussed as early as in
the 1960s in the biomedical communities, a well-
defined quantitative objective such as (2) was ab-
sent in the communications; see the work of Schnei-
derman (1965) and Geller (1984), for example. The
article by Storer and DeMets (1987) is the earliest
reference, to the best of my knowledge, that engages
the clinical readership with the idea of percentile
estimation. The authors point out the arbitrary es-
timation properties associated with the traditional
3+3 algorithm used in actual dose-finding studies
in cancer patients. The 3+3 algorithm identifies the
so-called maximum tolerated dose (MTD) using the
following dose-escalation rules after enrolling every
group of three subjects: let xj denote the dose given
to the jth group of subjects and suppose xj = dk;
then
xj+1 =
{
dk+1, if zk/nk < 0.33,
dk, if zk = 1 and nk = 3,
dk−1, if zk ≥ 2,
(3)
where nk and zk respectively denote the cumulative
sample size and number of toxicities at dose dk. The
trial will be terminated once a de-escalation occurs,
and the next lower dose will be called the MTD. In
the sequel, Storer (1989) deduced from the 3+3 al-
gorithm (3) that a cancer dose-finding study aims to
estimate the 33rd percentile (i.e., p= 0.33). While it
has now emerged that the target is likely lower than
the 33rd percentile with p being between 0.16 and
0.25, their work has shaped the subsequent develop-
ment of dose-finding methods in both the statistical
and biomedical literatures, and the MTD has since
been defined invariably as a dose associated with a
prespecified toxicity probability p.
O’Quigley, Pepe and Fisher (1990) proposed the
continual reassessment method (CRM) in 1990. The
CRM is the first model-based method in the modern
dose-finding literature. The main idea of the method
is to treat the next subject or group of subjects at
the dose with toxicity probability estimated to be
closest to the target p. Precisely, suppose we have
observations from the first j groups of subjects and
compute the posterior mean φˆj of φ given these ob-
servations. Then the next group of subjects will be
treated at
xj+1 = argmin
dk
|F (dk, φˆj)− p|.(4)
A similar idea is adopted in most model-based de-
signs proposed since 1990. One example is the esca-
lation with overdose control (EWOC) by Babb, Ro-
gatko and Zacks (1998), who applied the continual
reassessment notion but estimated the MTD with
respect to an asymmetric loss function which places
heavier penalties on overdosing than underdosing.
O’Quigley and Conaway (2010) and Tighiouart and
Rogatko (2010) in this special issue review the CRM
and the EWOC and their respective extensions. An-
other CRM-like design is the curve-free method by
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Gasparini and Eisele (2000) who estimated the dose-
toxicity curve using a Bayesian nonparametric
method in an attempt to avoid bias due to model
misspecification. Leung and Wang (2001) proposed
an analogous frequentist version that uses isotonic
regression for estimation. Other model-based designs
include the Bayesian decision-theoretic design
(Whitehead and Brunier (1995)), the logistic dose-
ranging strategy (Murphy and Hall (1997)), and
Bayesian c-optimal design (Haines, Perevozskaya, and
Rosenberger (2003)).
The late 1990s saw an increasing interest in algo-
rithm-based designs. Durham, Flournoy and Rosen-
berger (1997) proposed a biased coin design by which
the dose for the next subject is reduced if the current
subject has a toxic outcome, and the dose is esca-
lated with a probability p/(1 − p) otherwise. The
biased coin design is a randomized version of the
Dixon and Mood (1948) up-and-down design. Mo-
tivated by its similarity to the traditional design,
Cheung (2007) studied a class of stepwise proce-
dures that includes (3) as a special case. Yet an-
other algorithm-based method was proposed by Ji,
Li, and Bekele (2007) who made interim decisions
based on the posterior toxicity probability interval
associated with each dose. The impetus for these
algorithm-based designs is simplicity: the decision
rules can be charted prior to the trial, so that the
clinical investigators know exactly how doses will be
assigned based on the observed outcomes.
In order to make dose-finding techniques relevant
to clinical practice, statisticians have responded to
the realistically complicated clinical situations such
as time-to-toxicity endpoints (Cheung and Chap-
pell (2000)) and combination treatments (Thall et
al. (2003)). While the core dose-finding objective re-
mains a percentile estimation problem, the complex-
ity of dose-finding methods has grown rapidly in the
literature, with most innovations taking the model-
based approach. Thall (2010) in this special issue
will review the major development of these complex
designs.
Most (model-based) designs in the literature up
to this point take the myopic approach by which
the dose assignment is optimized with respect to the
next immediate subject without regard to the future
subjects. Bartroff and Lai (2010) in this issue break
away from this direction and propose a model-based
method from an adaptive control perspective. While
this work attempts to solve a specific Bayesian op-
timization problem, it also sets a new direction in
the modern dose-finding techniques; see Section 3 of
this article.
2.2 Why Model-Based Now
A model-based design allows borrowing strength
from information across doses. This characteristic
appeals to statisticians and clinicians alike, espe-
cially because of the typically small-to-moderate sam-
ple sizes seen in early-phase clinical studies. As clin-
icians begin to appreciate the crucial role of dose-
finding in the entire drug development program and
the value of statistical inputs to reconcile the ethi-
cal and research aspects in early-phase trials, their
discussions have revolved around model-based inno-
vations such as the CRM (Ratain et al. (1993)) and
the EWOC (Eisenhauer et al. (2000)). The increas-
ing number of applications in actual trials (Muller
et al. (2004)) indicates the clinical awareness and
readiness for these model-based methods.
When compared to the simplicity of algorithm-
based methods, the model-based approaches are com-
putationally complex and require special program-
ming before and during the implementation of a
trial. Thanks to the advances of computing algo-
rithms (e.g., Markov chain Monte Carlo) and com-
puter technology, however, trial planning with ex-
tensive simulation has become feasible. This being
the case, a full-scale dynamic programming can still
stretch the computing resource; see the article by
Bartroff and Lai (2010) for some comparison of com-
putational times. In addition, statistician-friendly
software has become increasingly available for the
planning and execution of these model-based de-
signs, for example, the dfcrm package in R (Cheung
(2008)). These indicators of computational matu-
rity transform the model-based designs into practi-
cal tools for dose-finding trials.
Finally, the development of dose-finding theory
and dose-response models in the past two decades
lends scientific rigor to the complexity of the model-
based methods. Indeed, the goal of this special issue
is to review the theoretical and modeling progress
made in the modern dose-finding literature, and
thereby demonstrate the full promise, and perhaps
challenges, of the model-based methods.
2.3 Some Theoretical Criteria
In a typical dose-finding trial, subjects are en-
rolled in small groups of size m≥ 1. The enrollment
plan is said to be fully sequential when m= 1. Let
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xi denote the dose given to the ith group of sub-
ject(s). Thus, the sequence {xi} forms the design of
a dose-finding study. As most dose-finding methods
are outcome-adaptive, each design point xi is ran-
dom and depends on the previous observation his-
tory. Evaluation of a dose-finding method therefore
involves the study of its design space with respect
to some ethical and estimation criteria. This section
will review some key dose-finding criteria including
coherence, rigidity, indifference intervals, and unbi-
asedness.
2.3.1 Coherence First, consider fully sequential tri-
als with m = 1, so that each human subject is an
experimental unit. An ethical principle, coined co-
herence by Cheung (2005), dictates that no escala-
tion should take place for the next enrolled subject
if the current subject experiences some toxicity, and
that dose reduction for the next subject is not ap-
propriate if the current subject has no sign of tox-
icity. Precisely, let Yi denote the toxicity outcome
of the ith subject. An escalation for the subject is
said to be coherent only when Yi−1 = 0; likewise, a
de-escalation is coherent only when Yi−1 = 1. Ex-
tending the notion of coherence for each move, one
can naturally define coherence as a property of a
dose-finding method:
Property 1 (Coherence). A dose-finding design
D is said to be coherent in escalation if with proba-
bility 1
PD(Ui > 0|Yi−1 = 1) = 0(5)
for all i, where Ui = xi− xi−1 is the dose increment
from subject i− 1 to i, and PD(·) denotes probabil-
ity computed under the design D. Analogously, the
design is said to be coherent in de-escalation if with
probability 1
PD(Ui < 0|Yi−1 = 0) = 0(6)
for all i.
It is important to note that coherence is motivated
by ethical concerns, and hence may not correspond
to efficient estimation of the dose-toxicity curve. For
example, in bioassay, an efficient design obtained by
sequentially maximizing some function of the infor-
mation may induce incoherent moves, and thus is
not appropriate for human trials; see the work of
McLeish and Tosh (1990), for example.
An algorithm-based design can explicitly incorpo-
rate dose decision rules that respect the coherence
principles; see the biased coin design. For a model-
based design, on the other hand, it is not imme-
diately clear whether coherence necessarily holds.
There are three general ways to ensure coherence in
practice. First, one could adopt model-based meth-
ods that have been proven coherent analytically. This
includes the one-stage Bayesian CRM. Second, one
could take a numerical approach. Let N denote the
sample size of a trial. Then the design space is com-
pletely generated by the first N − 1 binary toxic-
ity observations, and thus consists of 2N−1 possible
design outcomes. Therefore, one could establish co-
herence (for a given N ) by enumerating all possible
outcomes and verifying that there is no incoherent
move. In some cases, the number of outcomes can be
immensely reduced to the order of N ; see Theorem
1 in the article by Cheung (2005). Third, one could
enforce coherence by restriction when the model-
based dose assignment is incoherent. Applying co-
herence restrictions is common in practice (Faries
(1994)) and is the most straightforward approach for
complex designs. On the other hand, the restricted
moves need to be examined carefully lest they should
cause an incompatibility problem as defined by Che-
ung (2005).
In practice, the enrollment plan is often small-
group sequential, that is, m> 1, in order to reduce
the number of interim decisions and hence trial du-
ration. In this case, each group of subjects may be
viewed as an experimental unit. A generalized ver-
sion of Property 1 can be stated as:
Property 1′ (Group coherence). A dose-finding
design D is said to be group coherent in escalation
if with probability 1
PD(Ui > 0|Y¯i−1 ≥ p) = 0(7)
for all i, where Ui = xi− xi−1 now denotes the dose
increment from group i− 1 to i and Y¯i−1 is the ob-
served proportion of toxicities in group i− 1. Anal-
ogously, the design is said to be group coherent in
de-escalation if with probability 1
PD(Ui < 0|Y¯i−1 ≤ p) = 0(8)
for all i.
It is easy to see that (7) and (8) reduce to (5) and
(6), respectively, when m= 1 for p ∈ (0,1).
STOCHASTIC APPROXIMATION AND MODERN DOSE-FINDING 5
2.3.2 Rigidity and sensitivity A design sequence
{xn} is strongly consistent for θ if xn→ θ with prob-
ability 1. For trials allowing only a discrete number
of test doses as in (2), consistency means xn = ν
eventually with probability 1. Consistency, a desir-
able statistical property in general, has an ethical
connotation in dose-finding studies because it im-
plies all subjects enrolled after a certain time point
will be treated at ν, which is the desired dose.
Property 2 (Rigidity). A dose-finding design
D is said to be rigid if for every 0 < pL < π(ν) <
pU < 1 and all n≥ 1,
PD{xn ∈ Ipi(pL, pU)}< 1,
where Ipi(pL, pU ) = {x :pL ≤ π(x)≤ pU}.
It is easy to see that consistency excludes the
rigidity problem. In other words, Property 2 implies
that a design is inconsistent. In particular, rigid-
ity occurs when a CRM-like procedure is applied in
conjunction with nonparametric estimation. Hence,
such a nonparametric design is inconsistent. This is
quite interesting and somewhat counterintuitive, be-
cause nonparametric estimation is introduced with
an intention to remove bias and to enhance the
prospect of consistency.
To illustrate, consider a design that starts at dose
level 1, enrolls subjects in groups of size m= 2, and
assigns the next group at argmink |p˜k − p| where
p˜k is an estimate of π(dk) based on isotonic re-
gression, and the target is p = 0.20. Now suppose
that none of the subjects in the first group has a
toxic outcome. Then suppose the second group en-
ters the trial at dose level 2, with one of the two
experiencing toxicity. Based on these observations,
the isotonic estimates are p˜1 = 0.00 and p˜2 = 0.50,
which bring the trial back to dose level 1. From
this point on, because there is no parametric ex-
trapolation to affect the estimation of π(d2) by the
data collected at d1, the isotonic estimate p˜2 will
be no smaller than 0.50 regardless of what hap-
pens at d1, that is, |p˜2 − 0.20| ≥ 0.30. As a result,
|p˜1 − 0.20| < 0.30 ≤ |p˜2 − 0.20| if p˜1 ≤ 0.20. That is,
the trial will stay at dose level 1 even if there is a
long string of nontoxic outcomes there!
This example demonstrates that nonparametric
estimation and the sequential sampling plan together
cause rigidity through an “extreme” overestimate of
π(d2) based on small sample size. The probability of
this extreme overestimation is nonnegligible indeed:
if dose level 2 is the true MTD with π(d2) = 0.20,
then the probability that the trial is confined to the
suboptimal dose 1 is at least 0.36 by a simple bino-
mial calculation. Cheung (2002) constructed a sim-
ilar numerical example for the Bayesian nonpara-
metric curve-free method, and suggested that the
rigidity probability can be reduced by using an in-
formative prior to add smoothness to the estimation.
Due to ethical constraints such as coherence and
the discrete design space, it may be challenging to
achieve consistency without strong model assump-
tions. For example, the CRM has been shown to
be consistent under certain model misspecifications,
but is not generally so (Shen and O’Quigley (1996)).
In this context, Cheung and Chappell (2002) intro-
duced the indifference interval as a sensitivity mea-
sure of how close a design may approach ν on the
probability scale:
Property 3 (Indifference interval). The indif-
ference interval of a dose-finding design D exists and
is equal to p± δ if there exist N > 0 and δ ∈ (0, p)
such that
PD{xn ∈ Ipi(p− δ, p+ δ) for all n≥N}= 1.
Apparently, the smaller the half-width δ of a de-
sign’s indifference interval is, the closer the design
converges to the MTD; whereas a large δ indicates
the design is sensitive to the underlying π. The sen-
sitivity of the design D can thus be measured by
δ. Specifically, a design with half-width δ (for some
δ < p) will be called a δ-sensitive design.
It is clear that if a design D is consistent for ν,
then it is δ-sensitive; that is, one may choose δ so
that π(ν) ∈ p ± δ. Also, if D is δ-sensitive, then it
is nonrigid. Thus, while consistency appears to be
too difficult and nonrigidity too nondiscriminatory
for a dose-finding design, δ-sensitivity seems to be
a reasonable design property. Cheung and Chappell
(2002) prescribed a way to calculate the indifference
interval of the CRM, that is, the CRM is δ-sensitive.
Moreover, Lee and Cheung (2009) showed that the
CRM can be calibrated to achieve any δ level of
sensitivity. However, it should be noted that indif-
ference interval is an asymptotic criterion. As such, a
small δ does not necessarily yield good finite-sample
properties.
2.3.3 Unbiasedness The performance of a reason-
able dose-finding design is expected to improve as
the underlying dose-toxicity curve π becomes steep.
This property, called unbiasedness by Cheung (2007),
is formulated as follows:
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Fig. 1. Two dose-toxicity curves under which dose 3 is the
MTD with p = 0.20. A δ-sensitive design with δ = 0.06 will
eventually select doses 2 or 3 under the shallow curve (curve
1), but will be consistent for dose 3 under the steep curve
(curve 2). The horizontal dotted lines indicate the indifference
interval.
Property 4 (Unbiasedness). Let pi = π(di) de-
note the true toxicity probability at dose di. A de-
sign D is said to be unbiased if
(a) PD(xn = dk) is nonincreasing in pi′ for i
′ ≤ k,
and
(b) PD(xn = dk) is nondecreasing in pi for i > k.
For the special case with dk = ν and π(ν) = p, un-
biasedness implies that the probability of correctly
selecting ν increases as the doses above the MTD
become more toxic (i.e., pi≫ p), or the doses below
less toxic (i.e., pi′ ≪ p). In other words, the design
will select the true MTD more often as it becomes
more separated from its neighboring doses in terms
of toxicity probability. A design that satisfies this
special case is called weakly unbiased.
One may argue that δ-sensitive designs (e.g., the
CRM) are asymptotically weakly unbiased, in that
they will be consistent if the underlying dose-toxicity
curve π becomes sufficiently steep around the MTD;
see Figure 1 for an illustration. Unbiasedness has
been established only for few designs in the dose-
finding literature; an example is the class of stepwise
procedures (Cheung (2007)). In practice, extensive
simulations are usually required, and are often ade-
quate, to confirm that a design is (weakly) unbiased.
3. STOCHASTIC APPROXIMATION
3.1 The Robbins–Monro (1951) Procedure
Robbins and Monro (1951) introduced the first
formal stochastic approximation procedure for the
problem of finding the root of a regression function.
Precisely, let M(x) be the mean of an outcome vari-
able Y = Y (x) at level x, and suppose M(x) = α
has a unique root θ and supxE{Y 2(x)}<∞. Then
the stochastic approximation recursion approaches
θ sequentially:
xi+1 = xi − 1
ib
(Yi −α)(9)
for some constant b > 0. It is well established that
xn→ θ with probability 1. If in addition, the con-
stant b is chosen properly namely b < 2M ′(θ)≡ 2β,
then n1/2(xn − θ) will converge in distribution to a
normal variable with mean 0 and variance σ2{b(2β−
b)}−1 where σ2 = limx→θ var{Y (x)}; see the works
of Sacks (1958) and Wasan (1969).
It is immediately clear that (9) is applicable to
address objective (1) in a clinical trial setting with
M = π and α= p. For one thing, the recursion out-
put is coherent (Property 1) thus passing the first
ethical litmus test. It is also easy to see that a small-
group sequential version of (9), that is, replace Yi
with Y¯i, is group coherent (Property 1
′). There are,
however, several practical considerations.
The choice of b is crucial. In view of efficiency,
the asymptotic variance is minimized when we set
b= β, which is typically unknown in most applica-
tions. This leads to the idea of adaptive stochastic
approximation where b is replaced by a sequence bi
that is strongly consistent for β (Lai and Robbins
(1979)). However, when the sample size is small-to-
moderate, the numerical instability induced by the
adaptive choice bi may offset its asymptotic advan-
tage. In this article, for a reason described in Sec-
tion 4.2, we assume that a good choice of b is avail-
able.
The next practical issue is that (9) entails the
availability of a continuum of doses. This is seldom
feasible in practice. In drug trials, dose availability
is often limited by the dosage of a tablet. For treat-
ments involving combination of drugs administered
multiple times over a fixed period, each subsequent
dose may involve increasing doses and/or frequency
of different drugs. For example, Table 1 describes
the dose schedules of bortezomib used in a dose-
finding trial in patients with lymphoma (Leonard
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Table 1
Dose schedules of bortezomib used in Leonard et al. (2005)
Level Dose and schedule within cycle
1 0.7 mg/m2 on day 1 of each cycle
2 0.7 mg/m2 on days 1 and 8 of each cycle
3 0.7 mg/m2 on days 1 and 4 of each cycle
4 1.0 mg/m2 on days 1 and 4 of each cycle
5 1.3 mg/m2 on days 1 and 4 of each cycle
et al. (2005)). The first three levels prescribe borte-
zomib at a fixed dose 0.7 mg/m2 with increasing fre-
quency, whereas the next two increments apply the
same frequency with increasing bortezomib doses.
While we are certain that the risk for toxicity in-
creases over each level, there is no natural scale of
dosage (e.g., mg/m2). Thus, assuming that the toxi-
city probability π(x) is well defined on a continuous
range of x is artificial.
To tailor the stochastic approximation for the dis-
crete objective ν, an obvious approach is to round
the output of (9) to its closest dose at each iter-
ation. For example, suppose that the dose labels
are {1, . . . ,K}, that is, dk = k. Then a discretized
stochastic approximation may be expressed as
xi+1 =C
{
xi − 1
ib
(Y¯i − p)
}
,(10)
where C(x) is the rounded value of x if 0.5 ≤ x <
K + 0.5, and is set equal to 1 and K respectively if
x < 0.5 or >K +0.5. Unfortunately, the discretized
stochastic approximation is rigid (Property 2). To
illustrate, consider applying (10) with b = 0.2 and
a target p= 0.20 in a trial with x1 = 1 and m= 2.
Then no toxicity event in the first group, that is,
Y¯1 = 0, gives x2 = 2. Further suppose that the sec-
ond group has a 50% toxicity rate (Y¯2 = 0.5). This
will bring the trial back to x3 =C(2−0.75) = 1; it is
easy to see that the remaining subjects will receive
dose 1. To see how rigidity occurs for a general vari-
able type, we observe that since xi is an integer, the
update xi+1 according to (10) will stay the same
as xi if |(ib)−1(Y¯i − p)|< 0.5, whose probability ap-
proaches 1 at a rate of O(i−2) according to Cheby-
shev’s inequality if Yi has a finite variance. If Yi is
bounded (e.g., binary), the term C{(ib)−1(Y¯i − p)}
will always be zero as i becomes sufficiently large,
and will not contribute to future updates. This prob-
lem, called discrete barrier, is thus built by round-
ing and the fact that the design points take on a
discrete set of levels. In the context of the CRM,
Shen and O’Quigley (1996) pointed out similar dif-
ficulties in establishing the theoretical properties of
dose-finding methods due to the discrete barrier.
This is where the modern dose-finding literature de-
parts from the elegant stochastic approximation ap-
proach.
3.2 Stochastic Approximation and Model-Based
Methods
The Robbins–Monro stochastic approximation is
a nonparametric procedure in that the convergence
results depend only very weakly on the true under-
lying M(x). For the case of normal Y , interestingly,
Lai and Robbins (1979) showed that the recursion
output in (9) is identical to the solution x˜i+1 of
i∑
j=1
Yj −{α+ b(x˜j − x˜i+1)}= 0(11)
which amounts to maximum likelihood estimation of
θ under a simple linear regression model. This con-
nection between the stochastic approximation and
a model-based approach motivates the study of the
maximum likelihood recursion in the work of Wu
(1985), Wu (1986), and Ying and Wu (1997) for data
arising from the exponential family. In particular,
for binary Y , Wu (1985) proposed the logit-MLE
that uses the logistic working model
F (x, θ) =
p exp{b˜(x− θ)}
1− p+ p exp{b˜(x− θ)}
(12)
for some b˜ > 0
and replaces the estimating equation (11) with∑i
j=1{Yj − F (x˜j , x˜i+1)} = 0. Here, we focus on the
nonadaptive version, that is, where b˜ is a fixed con-
stant. A maximum likelihood version of the CRM
(4) would clearly yield the same design point as x˜i+1
if the design space was continuous. In this regard,
the likelihood CRM is an analogue of the logit-MLE
for the discrete objective ν.
In order to establish the asymptotic distribution
of the logit-MLE (and the maximum likelihood re-
cursion in general), Ying and Wu (1997) showed
that the sequence x˜i+1 is asymptotically equivalent
to an adaptive Robbins–Monro recursion; see the
proof of Theorem 3 in the article by Ying and Wu
(1997). While the justification of the model-based
logit-MLE relies on its asymptotic equivalence to
the nonparametric Robbins–Monro procedure, Wu
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(1985) showed by simulation that the former is su-
perior to the latter in finite-sample settings with bi-
nary data. Similarly, O’Quigley and Chevret (1991)
demonstrated that the CRM performs better than
the discretized stochastic approximation (10) for the
objective ν.
These observations regarding the stochastic ap-
proximation, the logit-MLE, and the CRM bear two
practical suggestions. First, in typical dose-finding
trial settings with binary data and small sample
sizes, a model-based approach seems to retain some
information that is otherwise lost when using non-
parametric procedures. This speculation is made
without assuming much confidence about the work-
ing model. Second, one may study the theoretical
(asymptotic) properties of the modern model-based
method (e.g., CRM) by tapping the rich stochastic
approximation literature, thus giving guidance on
the choice of design parameters such as b˜ in (12).
This can be achieved, of course, only if we can re-
solve the discrete barrier—we will return to this in
Section 4.2.
3.3 Stochastic Approximation and Adaptive
Control
Maximum likelihood recursion attempts to opti-
mize the prospect for the next subject by setting the
next design point at the current estimate of θ, and is
myopic in that it does not consider the dose assign-
ments of future subjects. The Robbins–Monro pro-
cedure is therefore myopic by (asymptotic) equiva-
lence. Lai and Robbins (1979) studied the adaptive
cost control aspect of the stochastic approximation
for normal Y where Cn =
∑n
i=1(xi − θ)2 is defined
as the cost of a design sequence {xi} at stage n.
Specifically, they showed that the cost of (9) is of
the order σ2 logn if b < 2β. Under some simple lin-
ear regression models, Han, Lai, and Spivakovsky
(2006) showed that the myopic Bayesian rule is op-
timal when the slope parameter is known. This sug-
gests that the myopic Robbins–Monro method may
also have good adaptive control properties.
The control aspect of the stochastic approxima-
tion is less clear for binary data. Bartroff and Lai
(2010) addressed the control problem by using tech-
niques in approximate dynamic programming to min-
imize some well-defined global risk, such as the ex-
pectation of the design cost Cn. The authors demon-
strated reduction of the global risk by nonmyopic
approaches when compared to the myopic ones in-
cluding the stochastic approximation and the logit-
MLE. The scope of the simulations, however, is con-
fined to situations where the logistic model correctly
specifies π. In addition, their approach is intended
for the continuous objective θ, instead of ν.
Further research on the use of nonmyopic
approaches in dose-finding is warranted, especially
for practical situations with a discrete set of test
doses. The design cost at stage n for the discrete ob-
jective ν can be analogously defined as C ′n =∑n
i=1(xi− ν)2. Then a dose-finding design D is con-
sistent if and only if limn→∞C
′
n is finite almost ev-
erywhere. As mentioned earlier, the myopic CRM is
not necessarily consistent (as it tries to treat each
subject at the current “best” dose). By contrast,
designs that spread out the design points (e.g., the
biased coin design) allow consistent estimation of
ν at the expense of the enrolled subjects. Neither
guarantees a finite limnC
′
n. An optimal D for the
infinite-horizon control of C ′n thus seems to resolve
the inherent tension between the welfare of enrolled
subjects (i.e., the cost is kept low) and the estima-
tion of ν (i.e., xn is consistent).
4. ONGOING RELEVANCE
4.1 Binary Versus Dichotomized Data
As mentioned earlier, with a binary outcome and
small samples, the Robbins–Monro procedure is gen-
erally less efficient than model-based methods, and
hence may not be suitable for clinical dose-finding
where the study endpoint is classified as toxic and
nontoxic. In many situations, however, the binary
toxic outcome T is defined by dichotomizing an ob-
servable biomarker expression Y , namely, T = 1(Y >
t0) for some fixed safety threshold t0, where 1(E) de-
notes the indicator of the event E. The biomarker
Y apparently contains more information than the
dichotomized T , and may be used to achieve the
dose-finding objective (1) with greater efficiency.
To illustrate, consider the regression model
Y =M(x) + σ(x)ǫ,(13)
where ǫ has a known distribution G with mean 0
and variance 1. Under (13), the toxicity probability
can be expressed as π(x) = 1−G[{t0−M(x)}/σ(x)]
and the continuous dose-finding objective (1) can be
shown to be equivalent to the solution to
f(x)≡M(x) + zpσ(x) = t0,(14)
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where zp is the upper pth percentile of G. To focus
on the comparison between the use of Y and T ,
suppose for the moment that a continuum of dose
x is available. Further suppose that a trial enrolls
patients in small groups of size m. Let xi denote the
dose given to the ith group, and Yij the biomarker
expression of the jth subject in the group. With this
experimental setup, we note that
Oi = Y¯i + [E{Si/σ(xi)}]−1zpSi(15)
is an unbiased realization of f(xi), where Si is the
sample standard deviation of the observations in
group i. The expectation in (15) can be computed
for any given G, because Si/σ(xi) depends on the
error variable ǫ but not M and σ under model (13).
In other words, Oi is observable and is a continuous
variable that can be used to generate a stochastic
approximation recursion
xi+1 = xi − (ib)−1(Oi − t0).(16)
The design {xn} generated by (16) is consistent for
θ under the condition that θ is the unique solution
to (14). This condition holds, for example, when M
is strictly increasing and σ is nondecreasing in x.
This is a reasonable assumption for many biological
measurements, for which the variability typically in-
creases with the mean. Furthermore, if b < 2β, where
β = f ′(θ) here, then the asymptotic variance of xn
is vO = limx→θ var(Oi){b(2β − b)}−1. In particular,
when ǫ is standard normal,
vO =
σ2(θ){1 +mz2p(λm − 1)}
mb(2β − b) ,
where
λm =
(m− 1)Γ2{(m− 1)/2}
2Γ2(m/2)
.
Now, instead of using the recursion (16), suppose
that we apply the logit-MLE based on the
dichotomized outcomes by solving
∑i
j=1{T¯j −
F (x˜j , x˜i+1)}= 0 where F is defined in (12). Then us-
ing the results in the article of Ying and Wu (1997),
we can show that
√
n(x˜n− θ) converges in distribu-
tion to a mean zero normal with variance vT = p(1−
p){mb˜(2β˜ − b˜)}−1 where β˜ ≡ π′(θ) = βG′(zp)/σ(θ).
The asymptotic variances of vO and vT are mini-
mized when b= β and b˜= β˜, respectively. Thus, the
optimal choice depends on unknown parameters. For
the purpose of comparing efficiencies, suppose we
Fig. 2. Asymptotic efficiency of xn based on recursion (16)
relative to the logit-MLE x˜n.
could set b and b˜ to their respective optimal values.
Then the variance ratio is equal to
vT
vO
=
p(1− p)
{G′(zp)}2{1 +mz2p(λm − 1)}
(17)
for normal noise, and also represents the asymptotic
efficiency of xn relative to x˜n. For m= 3, the ratio
(17) attains a minimum of 1.238 when p = 0.12 or
0.88. As shown in Figure 2, the efficiency gain can
be substantial for any group sizes larger than 2, es-
pecially when the target p is extreme.
4.2 Virtual Observations
A particular obstacle to the use of stochastic ap-
proximation is the discrete design space used in clin-
ical studies, which creates the discrete barrier (Sec-
tion 3.1). To overcome the discrete barrier, Cheung
and Elkind (2010) introduced the notion of virtual
observations. Precisely, the virtual observation of
the ith group of subjects is defined as
Vi =Oi + b(x
∗
i − xi),(18)
where x∗i denotes the assigned dose of the group
which can take values on a continuous conceptual
scale that represents an ordering of doses. In the
situations where the actual given dose xi can take
on any real value, we have x∗i ≡ xi and Vi ≡Oi, and
thus, the recursion (16) may be used to approach the
target dose θ. When xi is confined to {1, . . . ,K},
Cheung and Elkind (2010) proposed generating a
stochastic approximation recursion based on the vir-
tual observations:
x∗i+1 = x
∗
i −
1
ib
(Vi − t0),(19)
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and treating the next group of subjects at xi+1 =
C(x∗i+1). To initiate the virtual observation recur-
sion, one may set x∗1 = x1 ∈ {1, . . . ,K}.
Cheung and Elkind (2010) proved, under mild con-
ditions, that x∗i+1 generated by (19) is consistent
(hence nonrigid) for θb for some θb = ν ± 0.5, and
hence xi+1 for ν. Briefly, for any given b, consistency
will occur if the neighboring doses of the MTD are
sufficiently apart from the MTD in terms of toxicity
probability. This is in essence asymptotically weakly
unbiased as defined in Section 2.3.3, and can be eas-
ily derived from Propositions 2 and 3 of Cheung and
Elkind (2010).
With the use of continuous V ’s, the notion of co-
herence needs to be re-examined. In particular, the
virtual observation recursion (19) will de-escalate if
the biomarker expression of the current subjects has
a high average (Y¯i) or a large variability (Si). This
is a sensible dose-escalation principle for situations
where the variability increases proportionally to the
mean.
The idea of virtual observation is to create an ob-
jective function
h(x) =E(Vi|x∗i = x) = f{C(x)}+ b{x−C(x)}
that is defined on the real line, and has a local slope
at {1, . . . ,K}, such that the solution θ of (14) can be
approximated by the solution θb of h(x) = t0. Quite
importantly, since now the objective function h has
a known slope b around θb (under some Lipschitz-
type regularity conditions), we can use the same b
in the recursion (19) as in the definition of virtual
observations (18). This design feature enables us to
achieve optimal asymptotic variance without resort-
ing to adaptive estimation of the slope of the ob-
jective function. It is particularly relevant to early
phase dose-finding studies where adaptive stochastic
approximation can be unstable due to small sample
sizes.
5. LOOKING TO THE FUTURE
Statistical methodology for dose-finding trials is
by its nature an application-oriented discipline. Con-
sequently, much of the emphasis in the dose-finding
literature has been on empirical properties via simu-
lation. However, as the (model-based) methods be-
come increasingly complicated, it is imperative to
check their properties against some theoretical cri-
teria so as to avoid pathological behaviors that may
not be detected in aggregate via simulations; rather,
pathologies such as incoherence and rigidity are point-
wise properties that can be found by careful an-
alytical study. As a case in point, the virtual ob-
servation recursion (19) is presented in light of the
properties described in Section 2.3. Granted, as the
data content becomes richer, these theoretical crite-
ria have to be re-examined. Cheung (2010), in an-
other instance, extended the notion of coherence for
bivariate dose-finding in the context of phase I/II
trials—see the article by Thall (2010) for a review
of the bivariate dose-finding objective—and showed
how coherence can be used to simplify dose decisions
in the complex “black-box” approach of the bivari-
ate model-based methods, and to provide clinically
sensible rules.
The idea of virtual observation bridges the stochas-
tic approximation and the modern (model-based)
dose-finding literatures. As the Robbins–Monro
method has motivated a large number of extensions
and refinements for a wide variety of root-finding ob-
jectives, there exists a reservoir of ideas from which
we can borrow and apply to dose-finding methods
for specialized clinical situations. To name a few,
consult the works of Kiefer and Wolfowitz (1952)
for finding the maximum of a regression function,
and Blum (1954) for multivariate contour-finding.
While studying the analytical properties of model-
based designs in these specialized situations can be
difficult, connection to the theory-rich stochastic ap-
proximation procedures allows us to do so with rel-
ative ease and elegance, as is the case for the virtual
observation recursion (19). In this light, extending
the idea of virtual observations for data types other
than continuous and multivariate data appears to
be a promising “crosswalk” that warrants further
research.
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